Cetera Investment Advisers Purchases 5,809 Shares of Enovis Corporation (NYSE:ENOV)

Cetera Investment Advisers lifted its position in Enovis Corporation (NYSE:ENOV) by 30.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,591 shares of the company’s stock after acquiring an additional 5,809 shares during the quarter. Cetera Investment Advisers’ holdings in Enovis were worth $940,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ENOV. Farther Finance Advisors LLC lifted its holdings in shares of Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after acquiring an additional 536 shares during the last quarter. Quarry LP lifted its holdings in shares of Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 749 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after acquiring an additional 692 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Enovis by 57.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock worth $74,000 after acquiring an additional 725 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in shares of Enovis by 56.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,259 shares of the company’s stock worth $143,000 after acquiring an additional 1,173 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of NYSE ENOV opened at $28.74 on Wednesday. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53. Enovis Corporation has a 12 month low of $25.47 and a 12 month high of $49.83. The company has a 50 day simple moving average of $30.47 and a two-hundred day simple moving average of $34.96. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -2.02 and a beta of 1.70.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The firm had revenue of $564.50 million during the quarter, compared to analysts’ expectations of $555.80 million. During the same period in the previous year, the business posted $0.62 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. As a group, analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

ENOV has been the subject of several analyst reports. Wells Fargo & Company lowered their target price on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a report on Friday, August 8th. UBS Group reduced their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Needham & Company LLC reduced their price target on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Canaccord Genuity Group reduced their price target on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Evercore ISI reduced their price target on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $51.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.